Ocugen, Inc. (OCGN) Made Misstatements Regarding the Viability of its COVID-19 Vaccine Ocugen, Inc. issued a press release on February 2, 2021, announcing an agreement with Bharat Biotech International Limited,

Frequency Therapeutics, Inc. (FREQ) Made Misstatements Regarding the Potential of its Hearing Loss Treatment FX-322   According to the complaint, Frequency Therapeutics began its Phase 2a trial for FX-322 in

AcelRx Therapeutics, Inc. (ACRX) Made Misstatements in Advertising for its Lead Drug Candidate DSUVIA   During the relevant period, defendants made false and/or misleading statements and/or failed to disclose that:

Washington Prime Group, Inc. (WPG) Made Misstatements Regarding its Deteriorating Financial Condition WPG failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, defendants failed to

Aterian, Inc. (ATER) Made Misstatements Regarding its Business Prospects   On December 1, 2020, the Company announced that it had acquired the assets of “leading e-commerce business brands Mueller, Purstream,

RLX Technology Inc. (RLX) Made Misstatements Regarding Its Business Prospects The Registration Statement contained untrue statements of material fact.  Specifically, the Registration Statement omitted RLX’s exposure to China’s then-existing campaign

ChemoCentryx, Inc. (CCXI) Misled Investors Regarding the Company’s Concerns for User Safety After the market closed on November 25, 2019, ChemoCentryx, Inc. (CCXI) announced “Positive Topline Data from Pivotal Phase

Athenex, Inc. (ATNX) Misled Investors About the Efficacy of its Lead Drug Candidate and the Likelihood the FDA Would Approve its New Drug Application On August 7, 2019, Athenex, Inc.

Frequency Therapeutics, Inc. (FREQ) Made Misstatements Regarding the Potential of its Hearing Loss Treatment FX-322   Frequency Therapeutics began its Phase 2a trial for FX-322 in October 2019.  The trial